CSL Update on Enhanced Plasma Manufacturing
Open PDF
| Stock | CSL Ltd (CSL.ASX) |
|---|---|
| Release Time | 29 Jul 2026, 9:21 a.m. |
| Price Sensitive | Yes |
This feature provides summaries of price-sensitive announcements for companies followed by users on InvestorPA.
The summaries are generated by large language models so please interpret with care.
CSL Launches Clinical Trials for Enhanced Plasma Manufacturing
Key Points
- CSL to begin clinical trials for Horizon 2 process
- Horizon 2 aims to enhance immunoglobulin production
- Trials set to start in mid-2027 at Broadmeadows facility
Full Summary
CSL Limited announced the initiation of clinical trials for its Horizon 2 plasma manufacturing process, designed to significantly increase immunoglobulin production from plasma. The trials will start in mid-2027 at CSL's Broadmeadows facility. Horizon 2 is a patented technology that enables greater production from the same plasma base. CSL has engaged with the FDA and EMA to gather clinical evidence for regulatory approval. This initiative is part of CSL's broader focus on operational efficiencies and follows the planned expansion of its Kankakee facility.
Guidance
CSL expects clinical activities to commence in mid-2027.
Outlook
CSL anticipates that the Horizon 2 process will enhance operational efficiencies and improve immunoglobulin production capacity.
Sign in to get more information about the company, including guidance changes and other insights.
Sign In